Drug intelligence / Profile preview

Chongqing Medical Univ. GSK-3β compound [18F]8

Development stage: Unknown
Lead developer: Chongqing Medical University
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals

Overview

Chongqing Medical Univ. GSK-3β compound [18F]8: sourced facts only. name: "A potential GSK-3β tracer, [18F]8, was successfully radiolabeled." [PMID:37004924]; target: "A potential GSK-3β tracer, [18F]8, was successfully radiolabeled." [PMID:37004924]; developer: "Department of Radiological Medicine, College of Basic Medical Sciences, Chongqing Medical University, Chongqing 400016, PR China. Electronic address: [email protected]." [PMID:37004924]; modality: "A potential GSK-3β tracer, [18F]8, was successfully radiolabeled." [PMID:37004924]

Targets

GSK3 (Glycogen synthase kinase 3 beta)

Beyond the preview

Go deeper on Chongqing Medical Univ. GSK-3β compound [18F]8.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chongqing Medical Univ. GSK-3β compound [18F]8.